Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Bavarian Nordic, Bristol Myers Squibb, Byondis, Immunovant, Ipsen, Krystal, Mereo, Ovid, Takeda, Union.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adrenomed, Aslan, Celldex, Cohbar, Cynata, Geovax, Mitsubishi Tanabe, Novartis, Novavax, Odonate, Onconova, Protalix, PTC, Reithera, Trevena.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Audentes, Biontech, Sab, Vaccibody.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Gynesonics, Medtronic, Mission Bio.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Annovis, Ascletis, Aquestive, CNS, Entera, Immunic, Matinas, Orgenesis, Puma, Regeneron, Revive, Viiv.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aroa Biosurgery, Masimo, Verndari.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D Molecular, Acelrx, Albireo, Biolinerx, Epitopoietic Research, Jaguar Health, Kamada, Merck, Northwest, PCI, Pluristem, Qu, Trefoil, Turning Point, Verona.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Ansun, Arcturus, Ascletis, Blade, Botanix, GNI Group, I-Mab, Merck, Novavax, Romark Laboratories, SAB, Syndax.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cala Health, Edap, Gt Medical Technologies.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acepodia, Aligos, Arrowhead, Clovis, Deciphera, Follicum, GSK, Immatics, Immunicum, Immutep, Intravacc, Maxcyte, Novartis, Organicell, Poseida, Telix, The University of Texas MD Anderson Cancer Center, Ultimovacs, Vanda.